Cargando…

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption

BACKGROUND: Vacc-4x, a therapeutic HIV vaccine candidate has previously induced a significant reduction in viral load (VL) set-point compared to placebo upon interruption of combination anti-retroviral therapy (ART) (2007/1 study). This study, (2012/1), explored the potential to maintain Vacc-4x eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rockstroh, Jürgen K., Asmuth, David, Pantaleo, Giuseppe, Clotet, Bonaventura, Podzamczer, Daniel, van Lunzen, Jan, Arastéh, Keikawus, Mitsuyasu, Ronald, Peters, Barry, Silvia, Nozza, Jolliffe, Darren, Ökvist, Mats, Krogsgaard, Kim, Sommerfelt, Maja A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353572/ https://www.ncbi.nlm.nih.gov/pubmed/30699178 http://dx.doi.org/10.1371/journal.pone.0210965

Ejemplares similares

Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine
por: Ellefsen-Lavoie, K, et al.
Publicado: (2012)

The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study
por: Brekke, Kristin, et al.
Publicado: (2017)

Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial
por: Huang, Yunda, et al.
Publicado: (2017)

Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial
por: Brekke, Kristin, et al.
Publicado: (2014)

VaccImm: simulating peptide vaccination in cancer therapy
por: von Eichborn, Joachim, et al.
Publicado: (2013)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

P18-14 LB. Vacc-4x HIV p24-like peptide vaccine-associated increase of CD4 T-cells in chronically infected HIV-1 patients on antiretroviral therapy
por: Bengtsson, P, et al.
Publicado: (2009)

Small intestine enteroscopy: a new diagnostic tool not only in HIV infection
por: Traeder, Christian, et al.
Publicado: (2010)

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation
por: Hamilton, Kyra, et al.
Publicado: (2022)

The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
por: Goll, Johannes B., et al.
Publicado: (2023)

Decentralized Open Platform for Vaccination—A German Example: COVID-19-Vacc
por: Radonjic-Simic, Mirjana, et al.
Publicado: (2021)

Development of Immune-Specific Interaction Potentials and Their Application in the Multi-Agent-System VaccImm
por: Woelke, Anna Lena, et al.
Publicado: (2011)

Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
por: Goll, Johannes B., et al.
Publicado: (2023)

Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity
por: Bonjoch, Anna, et al.
Publicado: (2016)

Outgroup emotion processing in the vACC is modulated by childhood trauma and CACNA1C risk variant
por: Krautheim, Johannes T, et al.
Publicado: (2018)

Parents’ intention to vaccinate their child for COVID-19: A mixed-methods study (CoVAccS–wave 3)
por: Smith, Louise E., et al.
Publicado: (2022)

HIV Quasispecies Dynamics during Pro-Active Treatment Switching: Impact on Multi-Drug Resistance and Resistance Archiving in Latent Reservoirs
por: von Kleist, Max, et al.
Publicado: (2011)

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals
por: Winckelmann, Anni, et al.
Publicado: (2018)

Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)
por: Schäfer, Guido, et al.
Publicado: (2019)

Psychosocial factors affecting COVID-19 vaccine uptake in the UK: A prospective cohort study (CoVAccS – Wave 3)
por: Smith, Louise E., et al.
Publicado: (2023)

Visible‐Light‐Mediated Heterocycle Functionalization via Geometrically Interrupted [2+2] Cycloaddition
por: Popescu, Mihai V., et al.
Publicado: (2020)

638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results
por: Smith, Graham, et al.
Publicado: (2020)

Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions
por: Llano, Anuska, et al.
Publicado: (2013)

Second European Round Table on the Future Management of HIV: 10–11 October 2014, Barcelona, Spain
por: Rokx, Casper, et al.
Publicado: (2015)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

Leveraging WHO’s Global Benchmarking Tool to strengthen capacity in clinical trials oversight for public health emergencies: the GHPP VaccTrain model
por: Owusu Sekyere, Solomon, et al.
Publicado: (2022)

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma
por: Ali, Sahra, et al.
Publicado: (2020)

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2020)

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC
por: Ramón Santos, José, et al.
Publicado: (2014)

COVID-19 vaccination acceptability in the UK at the start of the vaccination programme: a nationally representative cross-sectional survey (CoVAccS – wave 2)
por: Sherman, S.M., et al.
Publicado: (2022)

Psychological factors associated with reporting side effects following COVID-19 vaccination: A prospective cohort study (CoVAccS – Wave 3)
por: Smith, Louise E., et al.
Publicado: (2023)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

VACuum INtubation (VACcIN) box restricts the exhaled air dispersion generated by simulated cough: description and simulation-based tests of an innovative aerosolization protective prototype
por: Issa, Rami, et al.
Publicado: (2021)

COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study
por: Ghosh, Subhadeep, et al.
Publicado: (2021)

Side-effect expectations from COVID-19 vaccination: Findings from a nationally representative cross-sectional survey (CoVAccS – wave 2)
por: Smith, Louise E., et al.
Publicado: (2022)

Using Temporal Covariance of Motion and Geometric Features via Boosting for Human Fall Detection
por: Ali, Syed Farooq, et al.
Publicado: (2018)

Preliminary X-ray crystallographic analysis of the secreted chorismate mutase from Mycobacterium tuberculosis: a tricky crystallization problem solved
por: Krengel, Ute, et al.
Publicado: (2006)

COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey
por: Sherman, Susan M., et al.
Publicado: (2020)

Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Use of antiviral drugs to reduce COVID-19 transmission
por: Mitjà, Oriol, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_20sbk57qeqt03b12ba7gf4p3te